Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome
NCT04494438Phase 3Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jul 2013
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Istituto Giannina Gaslini. Primary endpoint: Three months proteinuria at 3 months. Started Jul 2013; status: completed.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on NCT04494438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494438.